

Cite this: *Chem. Commun.*, 2019, 55, 5287Received 14th March 2019,
Accepted 28th March 2019

DOI: 10.1039/c9cc02051a

rsc.li/chemcomm

***N*-Azidoacetyl-D-glucosamine (GlcNAz) is a particularly useful tool in chemical biology as the azide is a metabolically stable yet accessible handle within biological systems. Herein, we report a practical synthesis of FmocAsn(*N*-Ac₃GlcNAz)OH, a building block for solid phase peptide synthesis (SPPS). Protecting group manipulations are minimised by taking advantage of the inherent chemoselectivity of phosphine-mediated azide reduction, and the resulting glycosyl amine is employed directly in the opening of Fmoc protected aspartic anhydride. We show potential application of the building block by establishing it as a substrate for enzymatic glycan extension using sugar oxazolines of varying size and biological significance with several *endo*-β-*N*-acetylglucosaminidases (ENGases). The added steric bulk resulting from incorporation of the azide is shown to have no or a minor impact on the yield of enzymatic glycan extension.**

N-Azidoacetyl-D-glucosamine (GlcNAz (1), Scheme 1A) is a carbohydrate motif that has proven to be a particularly useful tool in chemical biology; the azide is a metabolically stable¹ yet accessible handle within biological systems, allowing bioorthogonal visualisation after metabolic labelling.^{2,3} In some recent examples, the GlcNAz motif has been demonstrated as a useful component of synthetic probes used in chemical biology studies of glycan biology. For example Voadlo and co-workers synthesised a GlcNAz derivative (2-azidoacetamido-2-deoxy-5-fluoro-β-D-glucopyranosyl fluoride) and used it as an activity-based protein probe for successful isolation of a bacterial *N*-acetyl-β-D-glucosaminidase.⁴ In another study, Overkleeft and co-workers studied proteasomal recognition of fully synthetic *O*-GlcNAc and *O*-GlcNAz containing peptide inhibitors using activity-based protein

Efficient synthesis and enzymatic extension of an *N*-GlcNAz asparagine building block†

 Mikkel Haarslev Schröder Marqvorsen,^{ib}*^a Sivasinthujah Paramasivam,^b
Ward Doelman,^{ib}^a Antony John Fairbanks^{ib}^{bc} and Sander Izaäk van Kasteren^{ib}^a

profiling, showing minimal interference by the azide motif. Several other studies have utilized the related GalNAz motif for a variety of chemical biology studies.^{5–7}

As part of ongoing investigations into the antigen presentation biology of dendritic cells using bioorthogonal antigens,^{8–10} we sought to access peptide probes containing *N*-linked GlcNAz for a variety of chemical biology experiments. However, a literature survey revealed that such compounds had not been reported previously. Accordingly, we sought to develop a reliable and scalable synthetic approach to the suitably protected building block FmocAsn(*N*-Ac₃GlcNAz)OH (2, Scheme 1B), which would allow its use in the solid phase peptide synthesis (SPPS) of glycopeptides and other biological probes. Herein, we report a practical synthesis of glycosyl amino acid 2, and demonstrate its usefulness by establishing it as a substrate for enzymatic glycan extension using sugar oxazolines¹¹ of varying size and biological significance with several *endo*-β-*N*-acetylglucosaminidase enzymes (ENGases).¹²

A key synthetic challenge in the production of FmocAsn(*N*-Ac₃GlcNAz)OH (2) is installation of the glycosyl amine for subsequent coupling to a selectively protected aspartic acid derivative in the presence of the 2-azidoacetamido group. Whilst more convoluted and labour-intensive protecting group based strategies might meet this challenge, we envisioned a synthetic route in which a diazide 3 (Scheme 1B) was converted directly to the corresponding glycosyl amine *via* selective azide reduction. That such an approach may prove feasible was supported by the work of Wong and co-workers, who have previously published methodology for the chemoselective Staudinger-type reduction of azides using Me₃P in THF solution.¹³ Accordingly, diazide 3 was prepared using a scalable approach from the hydrochloride salt of glucosamine (4, Scheme 1B). The β-anomeric glycosyl acetate 5 was prepared without chromatographic purification, as reported by Bergmann and Zervas,¹⁴ and chloroacetylated to give 6. TiCl₄ mediated glycosyl chloride formation¹⁵ followed by double substitution with sodium azide in DMF afforded the desired diazide 3 in 63% yield (Scheme 1B), corresponding to 57% yield overall from compound 5.

^a Leiden Institute of Chemistry (LIC), Division of Bio-Organic Chemistry, Einsteinweg 55, Leiden, The Netherlands.


E-mail: m.h.s.marqvorsen@lic.leidenuniv.nl

^b Department of Chemistry, University of Canterbury, Private Bag 4800, Christchurch, 8140, New Zealand

^c Biomolecular Interaction Centre, University of Canterbury, Private Bag 4800, Christchurch, 8140, New Zealand

† Electronic supplementary information (ESI) available. See DOI: 10.1039/c9cc02051a





Scheme 1 (A) The chemical structure of GlcNAz; (B) synthetic route and intermediates towards the target compound FmocAsn(N-Ac₃GlcNAz)OH (2).

The Staudinger reduction of a glycosyl azide to afford the corresponding glycosyl amine has only been reported sporadically, mostly employing triphenylphosphine (or a resin bound version of it)¹⁶ as the reductant.^{16–20} We have previously reported the use of Me₂PhP for reduction of a glycosyl azide.²¹ Other phosphines have been used to obtain phosphinimides as targets,²² either for direct transformation into other desired functionalities, *e.g.* via the traceless Staudinger ligation,^{23,24} or for use in other reactions in which the phosphinimides act as nucleophiles.^{25–27} Wong and co-workers found that selective azide reduction to afford amines was possible in some cases using Me₃P. The selectivity seemed not to follow expectations based on steric considerations, but was instead predictable from the ¹H NMR chemical shifts of the *ipso*-protons next to each individual azide.¹³ We found that, indeed, upon addition of Me₃P (1 eq., 1 M in THF), a crude ¹H NMR spectrum revealed almost instant and complete conversion of the electron poor anomeric azide to give phosphinimide 7, whilst leaving the azidoacetyl group unaffected. Subsequent addition of 10 equivalents of water to the crude reaction mixture and agitation at room temperature led to fast hydrolysis whilst avoiding competitive anomerisation, thus affording clean conversion to the desired β-anomeric glycosyl amine 8.

We sought to maximise the practicality of the approach by coupling glycosyl amine 8 with aspartic anhydride²⁸ (9, Scheme 1B) to afford glycosyl amino acid building block 2 for SPPS. Crude glycosyl amine 8 was therefore dissolved in DMSO and Fmoc aspartic anhydride (9) was added. Indeed, after only 1 hour at room temperature all of the glycosyl amine had disappeared to give the desired product. Purification by precipitation was most practical on large scale, and a 5 mmol reaction afforded the desired FmocAsn(N-Ac₃GlcNAz)OH (2) in a 72% yield over three steps without any column chromatography.

GlcNAc-asparagine conjugates, either as discrete glycosyl amino acids or incorporated into larger peptides or proteins, act as efficient handles for the enzymatic attachment of a variety of *N*-glycan structures.²⁹ Numerous examples³⁰ of their application for the production of a variety of biologically active glycopeptides³¹ and glycoproteins³² exist. The utility of the FmocAsn(N-Ac₃GlcNAz)OH amino acid 2 would therefore be

significantly increased if the carbohydrate portion of this building block could be elaborated into more extended *N*-glycan structures for later applications as biological probes.

Previously we,²² and others,³³ have reported on the tolerance of ENGase enzymes¹³ to structural modifications of the acceptor for ENGase-catalysed glycosylation reactions using *N*-glycan oxazolines as donors.^{12,34} However, these studies did not investigate modification of the GlcNAc 2-acetamido group.


Although structural information is available on several of the family GH85 ENGases,³⁵ a particular concern was that the incorporation of an azide might significantly impair the ability of ENGases to attach *N*-glycan structures. Before application of the GlcNAz building block for the construction of more extended peptide structures, it was therefore deemed prudent to examine the ability of the monomeric glycosyl amino acid to act as an acceptor in a series of ENGase-mediated reactions.

The acetate protecting groups were removed from triacetate 2, to give the acceptor FmocAsn(N-GlcNAz)OH (10) as a substrate for ENGase-catalysed reactions (Scheme 2). Triol 10 was then subjected to a series of glycosylation reactions using several ENGase enzymes (WT Endo A,³⁶ WT Endo M,³⁷ and Endo M N175Q³⁸), and a variety of *N*-glycan oxazolines as donors (disaccharide oxazoline 11,³⁹ tetrasaccharide oxazoline 12,⁴⁰ and decasaccharide oxazoline 13;⁴¹ Table 1 and Scheme 2). The yields of the corresponding glycosylation reactions using FmocAsn(N-GlcNAc)OH (*i.e.* the analogous acceptor without the azide) are given for comparison where data is available.

Time course studies were also performed (see ESI[†]) revealing that neither the trisaccharide (14) nor the pentasaccharide (15) products were hydrolytic substrates for WT Endo A. Additionally, unsurprisingly the Endo M N175Q glycosynthase mutant did not hydrolyse any of the reaction products.

In all cases it can be seen that the azide-containing glycosyl amino acid was an effective acceptor substrate; all of the glycosylation yields were comparable to the corresponding GlcNAc acceptor, though slightly lower in two cases (entries 5 and 7). This series of experiments confirms that the ENGase enzymes tested (WT Endo A, WT Endo M, and the glycosynthase Endo M N175Q) are all able to tolerate the increased steric bulk of the azido-substituted





Scheme 2 Deacetylation of FmocAsn(*N*-Ac₃GlcNAz)OH **2**, and oxazoline substrates and products of ENGase-catalysed glycosylation reactions.

Table 1 ENGase-catalysed glycosylation of FmocAsn(*N*-GlcNAz)OH **10** with a variety of *N*-glycan oxazolines

Entry	Oxazoline donor	Product	ENGase	Yield ^a (%)	% Yield with corresponding GlcNAc acceptor ^a
1	11	14	WT Endo M	90	95 ^b
2	11	14	N175Q Endo M	6	—
3	11	14	WT Endo A	94	>95 ^b
4	12	15	WT Endo M	16	36 ^b /17 ^c
5	12	15	N175Q Endo M	60	69 ^c
6	12	15	WT Endo A	63	67 ^b
7	13	16	WT Endo M	20	30 ^c
8	13	16	N175Q Endo M	78	78 ^c

^a Determined by integration of product and acceptor HPLC peaks. ^b See ref. 41. Note the acceptor was the methyl ester and not the free acid. ^c See ref. 22.

acceptor within their active site. The excellent yield produced for glycosylation using the complex bi-antennary deca-saccharide oxazoline **13** using the N175Q Endo M mutant to give **16** is particularly noteworthy.

These positive preliminary results indicate that incorporation of glycosyl amino acid **2** into larger peptide structures, and subsequent ENGase-mediated extension of glycan structure should provide a reliable route to glycopeptide probes which incorporate azide functionality as a biorthogonal handle suitable for a variety of purposes (*vide supra*). The syntheses of such glycopeptides as tools for investigation of antigen presentation processes are currently in progress, and the results will be reported in due course.

Conflicts of interest

There are no conflicts to declare.

Notes and references

- T. Bakkum, T. van Leeuwen, A. J. C. Sarris, D. M. van Elsland, D. Poulcharidis, H. S. Overkleeft and S. I. van Kasteren, *ACS Chem. Biol.*, 2018, **13**, 1173–1179.
- E. Saxon and C. R. Bertozzi, *Science*, 2000, **287**, 2007–2010.
- E. Saxon, S. J. Luchansky, H. C. Hang, C. Yu, S. C. Lee and C. R. Bertozzi, *J. Am. Chem. Soc.*, 2002, **124**, 14893–14902.
- K. A. Stubbs, A. Scaffidi, A. W. Debowski, B. L. Mark, R. V. Stick and D. J. Vocadlo, *J. Am. Chem. Soc.*, 2008, **130**, 327–335.
- Q. Li, Z. Li, X. Duan and W. Yi, *J. Am. Chem. Soc.*, 2014, **136**, 12536–12539.
- L. Wen, Y. Zheng, K. Jiang, M. Zhang, S. M. Kondengaden, S. Li, K. Huang, J. Li, J. Song and P. G. Wang, *J. Am. Chem. Soc.*, 2016, **138**, 11473–11476.
- C. M. Gampe, H. Tsukamoto, E. H. Doud, S. Walker and D. Kahne, *J. Am. Chem. Soc.*, 2013, **135**, 3776–3779.
- J. D. McIntosh, M. A. Brimble, A. E. S. Brooks, P. R. Dunbar, R. Kowalczyk, Y. Tomabechi and A. J. Fairbanks, *Chem. Sci.*, 2015, **6**, 4636–4642.
- D. M. van Elsland, E. Bos, W. de Boer, H. S. Overkleeft, A. J. Koster and S. I. van Kasteren, *Chem. Sci.*, 2016, **7**, 752–758.
- J. B. Pawlak, B. J. Hos, M. J. van de Graaff, O. A. Megantari, N. Meeuwenoord, H. S. Overkleeft, D. V. Filippov, F. Ossendorp and S. I. van Kasteren, *ACS Chem. Biol.*, 2016, **11**, 3172–3178.
- A. J. Fairbanks, *Beilstein J. Org. Chem.*, 2018, **14**, 416–429.
- A. J. Fairbanks, *Chem. Soc. Rev.*, 2017, **46**, 5128–5146.
- P. T. Nyffeler, C.-H. Liang, K. M. Koeller and C.-H. Wong, *J. Am. Chem. Soc.*, 2002, **124**, 10773–10778.
- M. Bergmann and L. Zervas, *Ber. Dtsch. Chem. Ges.*, 1931, **64**, 975–980.



- 15 O. Boutoureira, G. J. L. Bernardes, M. Fernández-González, D. C. Anthony and B. G. Davis, *Angew. Chem., Int. Ed.*, 2012, **51**, 1432–1436.
- 16 R. S. Clark, S. Banerjee and J. K. Coward, *J. Org. Chem.*, 1990, **55**, 6275–6285.
- 17 E. Nuti, D. Cuffaro, F. D'Andrea, L. Rosalia, L. Tepshi, M. Fabbri, G. Carbotti, S. Ferrini, S. Santamaria, C. Camodeca, L. Ciccone, E. Orlandini, S. Nencetti, E. A. Stura, V. Dive and A. Rossello, *ChemMedChem*, 2016, **11**, 1626–1637.
- 18 B. G. Reddy, K. P. Madhusudan and Y. D. Vankar, *J. Org. Chem.*, 2004, **69**, 2630–2633.
- 19 F. Sajtos, L. Lázár, A. Borbás, I. Bajza and A. Lipták, *Tetrahedron Lett.*, 2005, **46**, 5191–5194.
- 20 T. Nishiyama, Y. Kusumoto, K. Okumura, K. Hara, S. Kusaba, K. Hirata, Y. Kamiya, M. Isobe, K. Nakano, H. Kotsuki and Y. Ichikawa, *Chem. – Eur. J.*, 2010, **16**, 600–610.
- 21 Y. Tomabechei, M. A. Squire and A. J. Fairbanks, *Org. Biomol. Chem.*, 2014, **12**, 942–955.
- 22 D. M. M. Jaradat, H. Hamouda and C. P. R. Hackenberger, *Eur. J. Org. Chem.*, 2010, 5004–5009.
- 23 A. Bianchi and A. Bernardi, *J. Org. Chem.*, 2006, **71**, 4565–4577.
- 24 Y. He, R. J. Hinklin, J. Chang and L. L. Kiessling, *Org. Lett.*, 2004, **6**, 4479–4482.
- 25 L. Kovács, E. Ósz, V. Domokos, W. Holzer and Z. Györgydeák, *Tetrahedron*, 2001, **57**, 4609–4621.
- 26 L. Kovács, E. Ósz and Z. Györgydeák, *Carbohydr. Res.*, 2002, **337**, 1171–1178.
- 27 K. J. Doores, Y. Mimura, R. A. Dwek, P. M. Rudd, T. Elliott and B. G. Davis, *Chem. Commun.*, 2006, 1401.
- 28 F. M. Ibatullin and S. I. Selivanov, *Tetrahedron Lett.*, 2009, **50**, 6351–6354.
- 29 T. B. Parsons, J. W. B. Moir and A. J. Fairbanks, *Org. Biomol. Chem.*, 2009, **7**, 3128–3140.
- 30 For some reviews see: (a) C. Li and L.-X. Wang, *Chem. Rev.*, 2018, **118**, 8359–8413; (b) L.-X. Wang and M. N. Amin, *Chem. Biol.*, 2014, **21**, 51–66; (c) L.-X. Wang and J. V. Lomino, *ACS Chem. Biol.*, 2012, **7**, 110–122; (d) A. J. Fairbanks, *Pure Appl. Chem.*, 2013, **85**, 1847–1863; (e) A. J. Fairbanks, *C. R. Chim.*, 2011, **14**, 44–58.
- 31 (a) Y. Tomabechei, G. Krippner, P. M. Rendle, M. A. Squire and A. J. Fairbanks, *Chem. – Eur. J.*, 2013, **19**, 15084–15088; (b) J. D. McIntosh, M. A. Brimble, A. E. S. Brooks, P. R. Dunbar, R. Kowalczyk, Y. Tomabechei and A. J. Fairbanks, *Chem. Sci.*, 2015, **6**, 4636–4642; (c) H. Li, S. Singh, Y. Zeng, H. Song and L. Wang, *Bioorg. Med. Chem. Lett.*, 2005, **15**, 895–898; (d) L.-X. Wang, H. Song, S. Liu, H. Lu, S. Jiang, J. Ni and H. Li, *ChemBioChem*, 2005, **6**, 1068–1074; (e) W. Huang, X. Zhang, T. Ju, R. D. Cummings and L.-X. Wang, *Org. Biomol. Chem.*, 2010, **8**, 5224–5233; (f) J. V. Lomino, A. Naegeli, J. Orwenyo, M. N. Amin, M. Aebi and L.-X. Wang, *Bioorg. Med. Chem.*, 2013, **21**, 2262–2270; (g) H. Hojo, H. Tanaka, M. Hagiwara, Y. Asahina, A. Ueki, H. Katayama, Y. Nakahara, A. Yoneshige, J. Matsuda, Y. Ito and Y. Nakahara, *J. Org. Chem.*, 2012, **77**, 9437–9446; (h) H. Cai, J. Orwenyo, J. Guenaga, J. Giddens, C. Toonstra, R. T. Wyatt and L.-X. Wang, *Chem. Commun.*, 2017, **53**, 5453–5456.
- 32 (a) P. Priyanka, T. B. Parsons, A. Miller, F. M. Platt and A. J. Fairbanks, *Angew. Chem., Int. Ed.*, 2016, **55**, 5058–5061; (b) T. Yamaguchi, M. N. Amin, C. Toonstra and L.-X. Wang, *J. Am. Chem. Soc.*, 2016, **138**, 12472–12485; (c) B. Li, H. Song, S. Hauser and L.-X. Wang, *Org. Lett.*, 2006, **8**, 3081–3084; (d) H. Ochiai, W. Huang and L.-X. Wang, *J. Am. Chem. Soc.*, 2008, **130**, 13790–13803; (e) M. N. Amin, W. Huang, R. M. Mizanur and L.-X. Wang, *J. Am. Chem. Soc.*, 2011, **133**, 14404–14417; (f) Q. Yang, Y. An, S. Zhu, R. Zhang, C. M. Loke, J. F. Cipollo and L.-X. Wang, *ACS Chem. Biol.*, 2017, **12**, 1665–1673.
- 33 (a) Y. Tomabechei, Y. Odate, R. Izumi, K. Haneda and T. Inazu, *Carbohydr. Res.*, 2010, **345**, 2458–2463; (b) J. Q. Fan, L. H. Huynh, B. B. Reinhold, V. N. Reinhold, K. Takegawa, S. Iwahara, A. Kondo, I. Kato and Y. C. Lee, *Glycoconjugate J.*, 1996, **13**, 643–652.
- 34 M. Fujita, S.-i. Shoda, K. Haneda, T. Inazu, K. Takegawa and K. Yamamoto, *Biochim. Biophys. Acta*, 2001, **1528**, 9–14.
- 35 (a) Z. Ling, M. D. L. Suits, R. J. Bingham, N. C. Bruce, G. J. Davies, A. J. Fairbanks, J. W. B. Moir and E. J. Taylor, *J. Mol. Biol.*, 2009, **389**, 1–9; (b) J. Yin, L. Li, N. Shaw, Y. Li, J. K. Song, W. Zhang, C. Xia, R. Zhang, A. Joachimiak, H.-C. Zhang, L.-X. Wang, Z.-J. Liu and P. Wang, *PLoS One*, 2009, **4**, e4658; (c) D. W. Abbott, M. S. Macauley, D. J. Vocadlo and A. B. Boraston, *J. Biol. Chem.*, 2009, **284**, 11676–11689.
- 36 K. Takegawa, K. Yamabe, K. Fujita, M. Tabuchi, M. Mita, H. Izu, A. Watanabe, Y. Asada, M. Sano, A. Kondo, I. Kato and S. Iwahara, *Arch. Biochem. Biophys.*, 1997, **338**, 22–28.
- 37 K. Fujita, K. Kobayashi, A. Iwamatsu, M. Takeuchi, H. Kumagai and K. Yamamoto, *Arch. Biochem. Biophys.*, 2004, **432**, 41–49.
- 38 (a) M. Umekawa, C. Li, T. Higashiyama, W. Huang, H. Ashida, K. Yamamoto and L.-X. Wang, *J. Biol. Chem.*, 2010, **285**, 511–521; (b) M. Umekawa, W. Huang, B. Li, K. Fujita, H. Ashida, L.-X. Wang and K. Yamamoto, *J. Biol. Chem.*, 2008, **283**, 4469–4479.
- 39 T. W. D. F. Rising, T. D. W. Claridge, N. Davies, D. P. Gamblin, J. W. B. Moir and A. J. Fairbanks, *Carbohydr. Res.*, 2006, **341**, 1574–1596.
- 40 T. W. D. F. Rising, C. D. Heidecke, J. W. B. Moir, Z. Ling and A. J. Fairbanks, *Chem. – Eur. J.*, 2008, **14**, 6444–6464.
- 41 (a) M. Umekawa, T. Higashiyama, Y. Koga, T. Tanaka, M. Noguchi, A. Kobayashi, S.-I. Shoda, W. Huang, L.-X. Wang, H. Ashida and K. Yamamoto, *Biochim. Biophys. Acta*, 2010, **1800**, 1203–1209; (b) A. Seko, M. Koketsu, M. Nishizonno, Y. Enoki, H. R. Ibrahim, L. R. Juneja, M. Kim and T. Yamamoto, *Biochim. Biophys. Acta*, 1997, **1335**, 23–32.

